50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

William Blair sets Outperform rating on Neurogene shares, $61 PT

EditorAhmed Abdulazez Abdulkadir
Published 03/21/2024, 10:32 AM
© Reuters.
NGNE
-

On Thursday, Neurogene Inc. (NASDAQ:NGNE) received an Outperform rating from William Blair, with a price target set at $61.00. The coverage initiation is based on the potential of Neurogene's lead gene therapy candidate, NGN-401, for the treatment of Rett syndrome, a rare genetic neurological disorder.

William Blair's analysis suggests that NGN-401, which includes a full-length human MECP2 transgene and Neurogene's proprietary EXACT technology, may offer regulated and consistent gene expression. This approach aims to minimize the risks of gene overexpression and the toxicities associated with it.

NGN-401 is currently undergoing a Phase I/II trial, which is particularly notable for its direct administration method that could enhance biodistribution in the brain, potentially leading to improved clinical outcomes.

The firm highlights the U.S. Food and Drug Administration's (FDA) decision to allow Neurogene to expedite its clinical trial by directly enrolling pediatric patients, bypassing the usual adult dosing studies. This move is seen as a testament to the strength of NGN-401's preclinical safety data.

Treating pediatric patients early is considered advantageous as they are more likely to gain maximum therapeutic benefits, which could lead to a robust dataset for the company.

The anticipation around the initial data from the Phase I/II trial of NGN-401, expected in the fourth quarter of 2024, is identified as a potential key catalyst for Neurogene's stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.